MALAKOFF, France, April 20, 2022--(BUSINESS WIRE)--Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, today announced that 1000 patients suffering from varicose veins have been treated with the SONOVEIN®. These patients have received non-invasive echotherapy treatment in several centres in Europe and Asia, all led by key-opinion leaders in their field.
The SONOVEIN, CE marked in 2019, is the only non-invasive ablation therapy device for varicose veins. Since 1998, vascular doctors have been looking for alternatives to the endovenous thermal ablation. This device allows a treatment without the use of a catheter, chemical injections, or incisions, thus leaves no scars. The procedure can be performed in a non-sterile environment.
"Without doubt, over the next few years, non-invasive treatment of leg veins using High Intensity Focused Ultrasound, also called echotherapy, is going to have a major impact on the way that varicose veins and venous leg ulcers are treated by specialist doctors and clinics. I am delighted to be involved with this revolution in treatment" explains Prof. Whiteley, consultant venous surgeon and founder of The Whiteley Clinics, UK. "Despite being launched just as the Covid pandemic hit, the team at Theraclion has done an amazing job at supporting the development of this exciting non-invasive technique." Prof. Whiteley, a renowned key opinion leader in varicose vein treatment has been an early adopter, using this disruptive technology since the CE mark of the 1st generation of the SONOVEIN.
Theraclion’s ambition is to revolutionize the $10 billioni varicose vein treatments and to give all patients access to non-invasive treatments.
As part of its strategy, Theraclion keeps exploring key partnership with significant corporate able to speed up the spread of its technology in the USA (seeking FDA clearance), in Europe and in Asia
Chronic Venous Insufficiency (CVI) and venous ulceration is a common health problem causing significant patient morbidity. Apart from the chronic physical and psychological disability caused to the individual, it also results in an enormous economic burden to the health care administration. Global prevalence rates of CVI are variable but may be as high as 40% among females and 17% among males1. Venous pathology generates around 5 million treatment procedures per year 2.
About Theraclion At Theraclion we believe that surgery, as we know it, is outdated. It converts optimistic patients into anxious individuals, brilliant doctors into exhausted system executors and stretches healthcare systems to the limit. We have disrupted this convention by creating extracorporeal treatment platforms. We replace surgery with a robotic treatment from outside the body using High Intensity Focussed Ultrasound (HIFU). Our leading edge echotherapy platforms are currently CE marked in non-invasive treatment of varicose veins with SONOVEIN® and of breast fibroadenomas and thyroid nodules with Echopulse®.
Located in Malakoff, near Paris, our employees live and breath innovation by extensive clinical research and harness artificial intelligence. The market of varicose veins treatment alone requires around 5 million procedures annually. It is a dynamic market in which we change paradigms by making non-invasive echotherapy the new standard.
For more information, please visit www.theraclion.com and our patient website https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI: 9695007X7HA7A1GCYD29
1 https://www.peertechz.com/articles/IJVSM-5-132.php 2 Millenium research Varicose Vein Device Market Study 2015
i Millenium research Varicose Vein Device Market Study 2015 | 2 Varicose veins – Felipe Collares
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005841/en/
David Auregan Chief Operating Officer david.auregan@theraclion.com
Anja Kleber VP Marketing, Market Access & Sales Francophonia anja.kleber@theraclion.com
Cassava Sciences, Inc.'s (NASDAQ:SAVA) a clinical stage biotechnology company, is developing a drug for Alzheimer - a neurodegenerative disease, affecting more than 35.7 million people worldwide (6 million in the US). In this article, we will review Cassava's product line and cash capacity to fund further research until FDA approval.
Much as Intuitive Surgical redefined the surgical field, this company is updating how abnormal heart rhythms are diagnosed.
Biotech stocks are down big since last summer. The media's focus on gene editing, messenger RNA (mRNA), and monoclonal antibodies may have waned, but some patients are already benefiting. Admittedly, shares of Regeneron are doing just fine.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the efficacy analysis have been submitted to the Vietnam Ministry of Health by Vinbiocare on April 13 and shared with Arcturus in parallel with this filing. The Phase 3 vaccine efficacy portion of this study enrolled over 16,000 participants. The trial met its primary endpoint of prevention of virologicall
Sunshine Biopharma Inc. (NASDAQ: SBFM) might be living the concept of being in the right place at the right time. This Canadian company is currently focusing on three product lines - the SBFM-PL4 COVID-19 treatment, the Adva-27a anticancer compound, and the Essential 9 nutritional supplements — and each is moving forward with positive results. In February, the company successfully closed an $8 million public offering and was uplisted to the Nasdaq Capital Market. Also, in February, the company e
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With this announcement, approximately 500 Canadians with CF ages 6-11 are now eligible for TRIKAFTA®. As a resul
Photo Illustration by The Daily Beast/GettyThanks to the success of an initial safety trial for an implantable device that can translate the brain’s electrical impulses into readable signals, we’re a step closer to being able to text—or otherwise interface with our devices—using just our thoughts.Best of all, this new brain-computer interface (BCI)—“brain modem,” if you will—doesn’t require a hole in your head. It does, however, require a hole in your chest. And that’s just one factor that could
The company's immunology drug Rinvoq was given the go-ahead to treat adult patients with moderate-to-severe ulcerative colitis.
Former surgeon general Jerome Adams is dubbing this month’s Gridiron Club dinner in Washington a “public health disaster” that should serve as a teachable moment. “A mass gathering occurring during a global pandemic — attended by government leaders, members of the media who’ve regularly reported on the pandemic, and even the Centers of Disease Control Prevention director and…
As mandates end, people are relying on one-way masking
Finch Therapeutics Group Inc (NASDAQ: FNCH) announced the layoff of 20% of its staff in a regulatory filing. The cuts will impact 37 full-time employees. The FDA in March placed a clinical hold on the Phase 3 trial for CP101, a donor-derived microbiome drug for Clostridioides difficile, as well as a partial hold on its new drug application. The FDA had asked for additional information about Finch's SARS-CoV-2 donor screening protocols. Due to the hold, the company paused enrollment in the late-s
Novavax, which is still awaiting a federal decision for its stand-alone Covid vaccine, received early results that suggest it can move forward with its testing for the single shot for both viruses.
The new BA.2.12.1 variant accounted for 19% of COVID cases in the U.S. last week, sharply increasing its spread from the week before.
COVID-19 cases are up more than 50% from three weeks ago in Ohio. Here's what Ohioans need to know for the next wave of the virus.
Is Merck stock a buy after the company guided to $10 billion in sales from its heart drugs? Is MRK stock a buy right now?
NHS transgender treatment for children is "bordering on ideological", Sajid Javid has warned.
State health officials say they are more concerned with hospitalizations, which are projected to be well below previous peaks.
We talked to two gut-health experts to find out what prebiotics are, how they can help with your riding performance, and what the best sources are.
Fauci, who has consulted multiple presidents about pandemics, weighs in on the end of mask mandates and the future of the pandemic.
Otonomy Inc (NASDAQ: OTIC) announced topline results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The trial demonstrated that a single intratympanic injection of 0.3 mg OTO-413 provided clinically meaningful treatment benefit versus placebo across multiple speech-in-noise (SIN) hearing tests and the Patient Global Impression of Change at consecutive time points (Days 57 and 85). 40% (8 of 20) of OTO-413 subjects demonstrated a clinically meaningful improvement on at